Trojan horse at cellular level for tumor gene therapies

Gene

Volumn 525, Issue 2, 2013, Pages 208-216

  Collet, Guillaume ^a   Grillon, Catherine ^a   Nadim, Mahdi ^a,b   Kieda, Claudine ^a  

^a CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^b Libragen Induchem Company   (France)

Author keywords

Exosome; Liposome; Nucleic acid delivery; Progenitor cell; Tumor targeting; Virus

Indexed keywords

ANGIOPOIETIN RECEPTOR; BETA GLUCURONIDASE; CD44V6 ANTIGEN; DOXORUBICIN; GANCICLOVIR; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN 1; ONCOLYTIC VIRUS; QUANTUM DOT; SHORT HAIRPIN RNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VITRONECTIN RECEPTOR;

ADENO ASSOCIATED VIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTECHNOLOGY; CANCER GENE THERAPY; DRUG POTENTIATION; ENDOSOME; EXOSOME; GLIOBLASTOMA; HUMAN; IMMUNOGENICITY; MESENCHYMAL STEM CELL; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AAV; AD; ADENO-ASSOCIATED VIRUSES; ADENOVIRUS; CANCER TARGETING GENE-VIRO-THERAPY; CTGVT; EGFR; ENDOTHELIAL PRECURSOR CELLS; EPCS; EPIDERMAL GROWTH FACTOR RECEPTOR; EXOSOME; GANCICLOVIR; GAOVT; GCV; GENE ARMED ONCOLYTIC VIRUS THERAPY; HERPES SIMPLEX VIRUS THYMIDINE KINASE; HIGHLY BRANCHED POLYAMIDOAMINE; HRE; HSV-TK; HYPOXIA RESPONSIVE ELEMENT; LIPOSOME; MDR1; MESENCHYMAL STEM CELLS; MSCS; MULTI DRUG RESISTANCE PROTEIN; NATURAL KILLERS; NK; NUCLEIC ACID DELIVERY; ONCOLYTIC VIRUSES; OVS; PAMAM; PEG; PEI; PLL; POLY(ETHYLENIMINE); POLY(L-LYSINE); POLYETHYLENE GLYCOL; POLYURETHANE-SHORT BRANCH POLYETHYLENIMINE; PROGENITOR CELL; PU-PEI; QD; QUANTUM DOTS; SPION; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; TELOMERASE REVERSE TRANSCRIPTASE; TERT; THL; THYMIDINE KINASE; TK; TRAIL; TROJAN HORSE LIPOSOME; TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR TARGETING; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; VIRUS;

ANIMALS; DRUG DELIVERY SYSTEMS; EXOSOMES; GANCICLOVIR; GENETIC THERAPY; HUMANS; LIPOSOMES; NEOPLASMS; ONCOLYTIC VIRUSES;

EQUIDAE;

EID: 84879879089     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.057     Document Type: Article

References (161)

1. Aboody K.S., et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12846-12851.
2. Aboody K.S., et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS One 2006, 1:e23.
3. Aboody K.S., et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro Oncol. 2006, 8:119-126.
4. Alemany R., Balague C., Curiel D.T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 2000, 18:723-727.
5. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29:341-345.
6. Asahara T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
7. Asahara T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 1999, 85:221-228.
8. Asahara T., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999, 18:3964-3972.
9. Asahara T., Kalka C., Isner J.M. Stem cell therapy and gene transfer for regeneration. Gene Ther. 2000, 7:451-457.
10. Babar I.A., et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E1695-E1704.
11. Bak X.Y., Yang J., Wang S. Baculovirus-transduced bone marrow mesenchymal stem cells for systemic cancer therapy. Cancer Gene Ther. 2010, 17:721-729.
12. Bangham A.D. Surrogate cells or Trojan horses. The discovery of liposomes. Bioessays 1995, 17:1081-1088.
13. Barajas M., et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001, 33:52-61.
14. Bielawska-Pohl A., et al. The anti-angiogenic activity of IL-12 is increased in iNOS-/-mice and involves NK cells. J. Mol. Med. (Berl) 2010, 88:775-784.
15. Boado R.J. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm. Res. 2007, 24:1772-1787.
16. Bray F., Jemal A., Grey N., Ferlay J., Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012, 13(8):790-801.
17. Burke B., Sumner S., Maitland N., Lewis C.E. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J. Leukoc. Biol. 2002, 72:417-428.
18. Buskens C.J., et al. A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens. Ann. Surg. 2003, 238:815-824. (discussion 825-6).
19. Cai Y., Liu X., Huang W., Zhang K., Liu X.Y. Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy. Acta Biochim. Biophys. Sin. (Shanghai) 2012, 44:535-543.
20. Carson A.R., et al. Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy. Cancer Res. 2012, 72(23):6191-6199.
21. Chen J.P., et al. Molecular therapy with recombinant antisense c-myc adenovirus for human gastric carcinoma cells in vitro and in vivo. J. Gastroenterol. Hepatol. 2001, 16:22-28.
22. Chen Z.Y., Liang K., Qiu R.X., Luo L.P. Enhancing microRNA transfection to inhibit survivin gene expression and induce apoptosis: could it be mediated by a novel combination of sonoporation and polyethylenimine?. Chin. Med. J. (Engl) 2011, 124:3592-3594.
23. Chen Y., et al. Development of an MRI-visible nonviral vector for siRNA delivery targeting gastric cancer. Int. J. Nanomedicine 2012, 7:359-368.
24. Cho W.K., et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol. Ther. 2004, 10:938-949.
25. Cline M.J. Perspectives for gene therapy: inserting new genetic information into mammalian cells by physical techniques and viral vectors. Pharmacol. Ther. 1985, 29:69-92.
26. Conrad C., et al. Linking transgene expression of engineered mesenchymal stem cells and angiopoietin-1-induced differentiation to target cancer angiogenesis. Ann. Surg. 2011, 253:566-571.
27. Coukos G., et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin. Cancer Res. 1999, 5:1523-1537.
28. Davidoff A.M., et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res. 2001, 7:2870-2879.
29. Debatin K.M., Wei J., Beltinger C. Endothelial progenitor cells for cancer gene therapy. Gene Ther. 2008, 15:780-786.
30. Deng W., Jia J. Endothelial progenitor cells as cellular vehicles to deliver oncolytic virus therapies to metastatic tumors: the "Trojan horse" approach. Med. Hypotheses 2008, 70:842-844.
31. Dickson P.V., et al. Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma. J. Pediatr. Surg. 2007, 42:48-53.
32. Ding L., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
33. Ding M., et al. Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene. PLoS One 2012, 7:e35153.
34. Dmitriev I., et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 1998, 72:9706-9713.
35. Dudek A.Z. Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy. Transl. Res. 2010, 156:136-146.
36. Dwyer R.M., Khan S., Barry F.P., O'Brien T., Kerin M.J. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res. Ther. 2010, 1:25.
37. Dwyer R.M., et al. Mesenchymal stem cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer. Stem Cells 2011, 29:1149-1157.
38. Ehtesham M., et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2002, 62:7170-7174.
39. Elzaouk L., Moelling K., Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp. Dermatol. 2006, 15:865-874.
40. Fevrier B., Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 2004, 16:415-421.
41. Fevrier B., et al. Cells release prions in association with exosomes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9683-9688.
42. Galanis E., et al. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol. Ther. 2012, 20:1998-2003.
43. Garcia-Castro J., et al. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Ther. 2005, 12:341-349.
44. Ghidoni R., Benussi L., Binetti G. Exosomes: the Trojan horses of neurodegeneration. Med. Hypotheses 2008, 70:1226-1227.
45. Gregoriadis G., Ryman B.E. Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Biochem. J. 1971, 124:58P.
46. Gu Y., et al. Lactation-related microRNA expression profiles of porcine breast milk exosomes. PLoS One 2012, 7:e43691.
47. Guo W., Fang B. Potentiation of oncolytic virotherapy with armed shRNA. Cancer Biol. Ther. 2009, 8:92-93.
48. Guo W., et al. Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther. 2006, 13:82-90.
49. Guo Z.S., Thorne S.H., Bartlett D.L. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 2008, 1785:217-231.
50. Halder J., et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 2006, 12:4916-4924.
51. Harrington K., et al. Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?. Hum. Gene Ther. 2002, 13:1263-1280.
52. He Y., et al. Ultrasound microbubble-mediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells. J. Exp. Clin. Cancer Res. 2011, 30:104.
53. Hemminki A. Portrait of a leader in immunotherapeutics: oncolytic viruses for treatment of cancer. Hum. Vaccin. Immunother. 2012, 8.
54. Herrlinger U., et al. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Hum. Gene Ther. 2000, 11:1429-1438.
55. Hu Y.C. Baculoviral vectors for gene delivery: a review. Curr. Gene Ther. 2008, 8:54-65.
56. Huang Q.D., et al. Cyclen-based cationic lipids for highly efficient gene delivery towards tumor cells. PLoS One 2011, 6:e23134.
57. Huang S., et al. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials 2011, 32:6832-6838.
58. Iankov I.D., et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol. Ther. 2007, 15:114-122.
59. Irie A., et al. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells. Cancer Gene Ther. 2006, 13:298-305.
60. Izquierdo-Useros N., et al. HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse?. PLoS Pathog. 2010, 6:e1000740.
61. Jevremovic D., et al. Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H494-H500.
62. Kam N.W., Liu Z., Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J. Am. Chem. Soc. 2005, 127:12492-12493.
63. Kanerva A., et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 2002, 5:695-704.
64. Kaplan J.M., et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 1999, 163:699-707.
65. Kay M.A., Glorioso J.C., Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 2001, 7:33-40.
66. Kharaziha P., Ceder S., Li Q., Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. Biochim. Biophys. Acta 2012, 1826:103-111.
67. Kichler A., Leborgne C., Coeytaux E., Danos O. Polyethylenimine-mediated gene delivery: a mechanistic study. J. Gene Med. 2001, 3:135-144.
68. Knoop K., et al. Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Mol. Ther. 2011, 19:1704-1713.
69. Komarova S., Kawakami Y., Stoff-Khalili M.A., Curiel D.T., Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 2006, 5:755-766.
70. Kon T., et al. Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA. Transl. Cancer Res. 2012, 1:4-14.
71. Kosaka N., et al. Exosomal tumor-suppressive microRNAs as novel cancer therapy: "exocure" is another choice for cancer treatment. Adv. Drug Deliv. Rev. 2012, 65(3):376-382.
72. Kwon O.J., Kim P.H., Huyn S., Wu L., Kim M., Yun C.O. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin. Cancer Res. 2010, 16:6071-6082.
73. Lal R., Harris D., Postel-Vinay S., de Bono J. Reovirus: rationale and clinical trial update. Curr. Opin. Mol. Ther. 2009, 11:532-539.
74. Landen C.N., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65:6910-6918.
75. Lee H., Jeong J.H., Park T.G. PEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicity. J. Control. Release 2002, 79:283-291.
76. Lee Y., El Andaloussi S., Wood M.J. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum. Mol. Genet. 2012, 21:R125-R134.
77. Li C., Bowles D.E., van Dyke T., Samulski R.J. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 2005, 12:913-925.
78. Li J., et al. The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma. Nanotechnology 2011, 22:435101.
79. Li J.M., et al. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking. Biomaterials 2012, 33:2780-2790.
80. Liu X.Q., Song W.J., Sun T.M., Zhang P.Z., Wang J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol. Pharm. 2011, 8:250-259.
81. Liu P., Yu H., Sun Y., Zhu M., Duan Y. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials 2012, 33:4403-4412.
82. Liu X., et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Ther. 2012, 19:49-57.
83. Liu X.Y., Li H.G., Zhang K.J., Gu J.F. Strategy of cancer targeting gene-viro-therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy. Curr. Pharm. Biotechnol. 2012, 13:1761-1767.
84. Mahendra G., et al. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther. 2005, 12:26-34.
85. Maitra R., Ghalib M.H., Goel S. Reovirus: a targeted therapeutic-progress and potential. Mol. Cancer Res. 2012, 10:1514-1525.
86. Majhen D., Ambriovic-Ristov A. Adenoviral vectors-how to use them in cancer gene therapy?. Virus Res. 2006, 119:121-133.
87. Miele E., Spinelli G.P., Di Fabrizio E., Ferretti E., Tomao S., Gulino A. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int. J. Nanomedicine 2012, 7:3637-3657.
88. Mittelbrunn M., et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2011, 2:282.
89. Morris D.G., et al. REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Invest. New Drugs 2012, 10.1007/s10637-012-9865-z.
90. Mukherjee A., et al. Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor. Mol. Ther. 2009, 17:623-631.
91. Nakamura K., et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004, 11:1155-1164.
92. Nicklin S.A., et al. Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Lett. 2003, 201:165-173.
93. Niess H., et al. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann. Surg. 2011, 254:767-774. (discussion 774-5).
94. Okada T., Ozawa K. Vector-producing tumor-tracking multipotent mesenchymal stromal cells for suicide cancer gene therapy. Front. Biosci. 2008, 13:1887-1891.
95. Okada Y., Okada N., Mizuguchi H., Hayakawa T., Nakagawa S., Mayumi T. Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma. Cancer Gene Ther. 2005, 12:608-616.
96. O'Loughlin A.J., Woffindale C.A., Wood M.J. Exosomes and the emerging field of exosome-based gene therapy. Curr. Gene Ther. 2012, 12:262-274.
97. Ong H.T., Hasegawa K., Dietz A.B., Russell S.J., Peng K.W. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 2007, 14:324-333.
98. O'Riordan C.R., et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 1999, 10:1349-1358.
99. Ozawa C.R., Springer M.L., Blau H.M. A novel means of drug delivery: myoblast-mediated gene therapy and regulatable retroviral vectors. Annu. Rev. Pharmacol. Toxicol. 2000, 40:295-317.
100. Pan J.G., Zhou X., Luo R., Han R.F. The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma. Med. Oncol. 2012, 29:1938-1947.
101. Pardridge W.M. Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb. Protoc. 2010, 10.1101/pdb.prot5407.
102. Patel M.M., Goyal B.R., Bhadada S.V., Bhatt J.S., Amin A.F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009, 23:35-58.
103. Pereboeva L., Komarova S., Mikheeva G., Krasnykh V., Curiel D.T. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 2003, 21:389-404.
104. Pille J.Y., et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 2006, 17:1019-1026.
105. Pisters L.L., et al. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin. Cancer Res. 2004, 10:2587-2593.
106. Ponnazhagan S., Curiel D.T., Shaw D.R., Alvarez R.D., Siegal G.P. Adeno-associated virus for cancer gene therapy. Cancer Res. 2001, 61:6313-6321.
107. Ponnazhagan S., et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res. 2004, 64:1781-1787.
108. Popkov M., Jendreyko N., McGavern D.B., Rader C., Barbas C.F. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res. 2005, 65:972-981.
109. Post D.E., Van Meir E.G. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003, 22:2065-2072.
110. Pouton C.W., Lucas P., Thomas B.J., Uduehi A.N., Milroy D.A., Moss S.H. Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids. J. Control. Release 1998, 53:289-299.
111. Power A.T., Bell J.C. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther. 2008, 15:772-779.
112. Power A.T., et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 2007, 15:123-130.
113. Rai K., et al. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther. 2011, 10:1720-1727.
114. Rajendran L., et al. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11172-11177.
115. Ramezani A., Hawley T.S., Hawley R.G. Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 2003, 101:4717-4724.
116. Raykov Z., Balboni G., Aprahamian M., Rommelaere J. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int. J. Cancer 2004, 109:742-749.
117. Robson T., Hirst D.G. Transcriptional targeting in cancer gene therapy. J. Biomed. Biotechnol. 2003, 2003:110-137.
118. Ruan H., Su H., Hu L., Lamborn K.R., Kan Y.W., Deen D.F. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 2001, 3:255-263.
119. Rudzinski W.E., Aminabhavi T.M. Chitosan as a carrier for targeted delivery of small interfering RNA. Int. J. Pharm. 2010, 399:1-11.
120. Schmidt C. Amgen spikes interest in live virus vaccines for hard-to-treat cancers. Nat. Biotechnol. 2011, 29:295-296.
121. Schneider A., Simons M. Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res. 2012.
122. Shah K., Tung C.H., Breakefield X.O., Weissleder R. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol. Ther. 2005, 11:926-931.
123. Shen W., Wang C.Y., Wang X.H., Fu Z.X. Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J. Exp. Clin. Cancer Res. 2009, 28:81.
124. Shinozaki K., et al. Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. Gene Ther. 2006, 13:52-59.
125. Sims T.L., et al. Neural progenitor cell-mediated delivery of interferon beta improves neuroblastoma response to cyclophosphamide. Ann. Surg. Oncol. 2008, 15:3259-3267.
126. Song J.S. Adenovirus-mediated suicide SCLC gene therapy using the increased activity of the hTERT promoter by the MMRE and SV40 enhancer. Biosci. Biotechnol. Biochem. 2005, 69:56-62.
127. Soriano P., et al. Targeted and nontargeted liposomes for in vivo transfer to rat liver cells of a plasmid containing the preproinsulin I gene. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:7128-7131.
128. Spagnou S., Miller A.D., Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 2004, 43:13348-13356.
129. Stender S., et al. Adeno-associated viral vector transduction of human mesenchymal stem cells. Eur. Cell. Mater. 2007, 13:93-99. (discussion 99).
130. Stoff-Khalili M.A., et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res. Treat. 2007, 105:157-167.
131. Stoff-Khalili M.A., et al. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control. Breast Cancer Res. Treat. 2008, 108:43-55.
132. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002, 62:3603-3608.
133. Sun X.Y., Nong J., Qin K., Warnock G.L., Dai L.J. Mesenchymal stem cell-mediated cancer therapy: a dual-targeted strategy of personalized medicine. World J. Stem Cells 2011, 3:96-103.
134. Szybalska E.H., Szybalski W. Genetics of human cess line. IV. DNA-mediated heritable transformation of a biochemical trait. Proc. Natl. Acad. Sci. U. S. A. 1962, 48:2026-2034.
135. Tabatabai G., Wick W., Weller M. Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach?. Discov. Med. 2011, 11:529-536.
136. Tan A., Rajadas J., Seifalian A.M. Exosomes as nano-theranostic delivery platforms for gene therapy. Adv. Drug Deliv. Rev. 2012, 65(3):357-367.
137. Tang C., Russell P.J., Martiniello-Wilks R., Rasko J.E., Khatri A. Concise review: nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?. Stem Cells 2010, 28:1686-1702.
138. Taratula O., Garbuzenko O., Savla R., Wang Y.A., He H., Minko T. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr. Drug Deliv. 2011, 8:59-69.
139. Tazzyman S., Lewis C.E., Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int. J. Exp. Pathol. 2009, 90:222-231.
140. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2:569-579.
141. Varma N.R., et al. Endothelial progenitor cells (EPCs) as gene carrier system for rat model of human glioma. PLoS One 2012, 7:e30310.
142. Wahlgren J., et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res. 2012, 40:e130.
143. Wang S., Balasundaram G. Potential cancer gene therapy by baculoviral transduction. Curr. Gene Ther. 2010, 10:214-225.
144. Wang T., Upponi J.R., Torchilin V.P. Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int. J. Pharm. 2012, 427:3-20.
145. Wilcox M.E., et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J. Natl. Cancer Inst. 2001, 93:903-912.
146. Xia C.F., Boado R.J., Zhang Y., Chu C., Pardridge W.M. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J. Gene Med. 2008, 10:306-315.
147. Xie M., et al. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines. Apoptosis 2009, 14:1086-1094.
148. Xin H., et al. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007, 25:1618-1626.
149. Yang Y.P., et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 2012, 33:1462-1476.
150. Yao X., et al. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther. 2009, 16:1395-1404.
151. Yoo J.Y., et al. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol. Ther. 2007, 15:295-302.
152. Yoo J.Y., et al. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther. 2008, 15:635-651.
153. Yuan X., Hu J., Belladonna M.L., Black K.L., Yu J.S. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res. 2006, 66:2630-2638.
154. Zeng J., Du J., Zhao Y., Palanisamy N., Wang S. Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells. Stem Cells 2007, 25:1055-1061.
155. Zhang H.G., Grizzle W.E. Exosomes and cancer: a newly described pathway of immune suppression. Clin. Cancer Res. 2011, 17:959-964.
156. Zhang Y., Pardridge W.M. Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy. Pharm. Res. 2009, 26:1059-1063.
157. Zhang Y., Zhang Y.F., Bryant J., Charles A., Boado R.J., Pardridge W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 2004, 10:3667-3677.
158. Zhang Z., et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin. Cancer Res. 2006, 12:4933-4939.
159. Zhang Y., Wang Y., Boado R.J., Pardridge W.M. Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm. Res. 2008, 25:400-406.
160. Zhao Y., et al. Targeted suicide gene therapy for glioma using human embryonic stem cell-derived neural stem cells genetically modified by baculoviral vectors. Gene Ther. 2012, 19:189-200.
161. Zhu W., Wei L., Zhang H., Chen J., Qin X. Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo. J. Exp. Clin. Cancer Res. 2012, 31:51.